Keros Therapeutics Inc share price logo

Keros Therapeutics Inc Share Price

NASDAQ: KROS

Small Cap

$11.13

-0.07

(-0.62%)

as on

Keros Therapeutics Inc Stock Performance

as on April 14, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $10.78
    $11.33
    downward going graph

    3.14%

    Downside

    1.80%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $10.42
    $22.55
    downward going graph

    6.42%

    Downside

    102.61%

    Upside

    downward going graph

Keros Therapeutics Inc share price movements today

Previous Close
$11.21
Open
$11.20
Volume
525.0K
Day's Low - High
$10.78 - $11.33
52 Week Low - High
$10.42 - $22.55

Keros Therapeutics Inc Historical Returns

1 Month Return
+ 1.18 %
3 Month Return
-42.91 %
1 Year Return
-12.48 %
3 Year Return
-71.26 %
5 Year Return
0 %

Keros Therapeutics Inc Stock Fundamentals & Key Indicators

Check Keros Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$341.4M

EPS (TTM)

-4.6733

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

4.87

Industry PE ratio

-4.399805825242718

PEG Ratio

0

EBITDA

72.1M

Revenue (TTM)

244.1M

Profit Margin

35.65%

Return On Equity TTM

19.90%

Keros Therapeutics Inc Stock Valuation

Track how Keros Therapeutics Inc P/E has moved over time to understand its valuation trends.

Keros Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (-64.50x)

March 31, 2025

Industry (-4.40x)

April 14, 2026

Today (4.87x)

April 14, 2026

Highest (43.55x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: 4.87x

Keros Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Keros Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Keros Therapeutics Inc image
Keros Therapeutics Inc
BUY$341.4MNA4.8735.65%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$42.7B140.76%138.848.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$111.0B102.67%28.532.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$35.6BNA124.865.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$79.2B55.14%18.0531.41%

Stock Returns calculator for Keros Therapeutics Inc Stock including INR - Dollar returns

The Keros Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Keros Therapeutics Inc investment value today

Current value as on today

₹94,762

Returns

-₹5,238

(-5.24%)

Returns from Keros Therapeutics Inc Stock

-₹12,637 (-12.64%)

Dollar Impact

₹7,400 (+7.4%)

Analyst Recommendation on Keros Therapeutics Inc Stock

Based on 16 analysts

BUY

93.75%

Buy

6.25%

Hold

0.00%

Sell

Based on 16 analysts, 93.75% of analysts recommend a 'BUY' rating for Keros Therapeutics Inc. Average target price of $22.57

Keros Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Keros Therapeutics Inc.

What analysts predicted

50.69%UPSIDE

Target Price

$22.57

Current Price

$11.13

Analyzed by

16 Analysts

Target

$22.57

Keros Therapeutics Inc target price $22.57, a slight upside of 50.69% compared to current price of $11.13. According to 16 analysts rating.

Keros Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Keros Therapeutics Inc Stock has decreased by -21% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-21% versus previous 30 day period

Keros Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
0
0
0
0
0
3
211
18
14
0
Gross Profit
0
0
0
0
0
2
211
17
13
0
Operating Income
-43
-46
-48
-50
-58
-53
152
-39
-15
-26
EBITDA
-38
-39
-48
-50
-58
-29
152
-32
-8
-28
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-39
-40
-43
-45
-52
-45
158
-32
-8
-24
Income Tax Expense
0
3
0
-
-
0
10
-2
-1
-1
Net Income
-39
-40
-43
-45
-52
-46
148
-30
-7
-23
Net Profit Margin
-493000.00%
-28141.96%
-51944.58%
-122316.22%
-13648.45%
-1513.02%
70.27%
-168.96%
-51.04%
-6093.77%

Keros Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
10
10
2
20
20
0
3
244
Gross Profit
0
-7
0
20
-1
0
3
242
Operating Income
-1
-10
-46
-56
-114
-169
-210
70
EBITDA
0
-11
-44
-56
-104
-152
-185
72
Interest Expense
0
0
0
0
0
-
-
-
Depreciation
0
0
0
0
0
0
1
1
Income Before Tax
-1
-12
-45
-56
-104
-152
-187
91
Income Tax Expense
0
0
0
2
0
0
0
4
Net Income
-1
-12
-45
-58
-104
-152
-187
87
Net Profit Margin
-13.35%
-123.44%
-1814.44%
-292.26%
-523.40%
-101319.21%
-5277.55%
35.65%

Keros Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-40
-43
-45
-52
-46
148
-30
-7
-23
Operating Cash Flow
-25
-44
-39
-30
-46
161
-29
3
-27
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
69
156
3
155
75
0
0
0
-378
Change in Cash
43
111
-36
125
29
160
-30
3
-406

Keros Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-12
-45
-58
-104
-152
-187
87
Operating Cash Flow
-15
-36
-62
-70
-124
-160
107
Investing Cash Flow
0
0
-1
-1
-2
-1
-1
Financing Cash Flow
0
296
28
120
178
391
-378
Change in Cash
-16
258
-34
49
51
229
-272

Global Institutional Holdings in Keros Therapeutics Inc

Funds
Holdings
Jacobs Levy Equity Management, Inc.
3.9%
ADAR1 Capital Management LLC
13.27%
D. E. Shaw & Co LP
3.83%
Geode Capital Management, LLC
3.22%
Renaissance Technologies Corp
3%
See all

Insights on Keros Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 63.3% return, outperforming this stock by 134.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 38.7% return, outperforming this stock by 51.2%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, KROS stock has moved down by -8.9%

About Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
OrganisationKeros Therapeutics Inc
Headquarters1050 Waltham Street, Lexington, MA, United States, 02421
IndustryBiotechnology
CEODr. Jasbir S. Seehra Ph.D.
E-voting on sharesClick here to vote

Key Management of Keros Therapeutics Inc

Name

Title

Dr. Jasbir S. Seehra Ph.D.

President, CEO & Director

Mr. Keith C. Regnante MBA

Chief Financial Officer

Ms. Esther Cho J.D.

Chief Legal Officer & Secretary

Dr. Lorena Lerner Ph.D.

Chief Scientific Officer

FAQs

What is Keros Therapeutics Inc share price today?

Keros Therapeutics Inc share price today is $11.13 as on at the close of the market. Keros Therapeutics Inc share today touched a day high of $11.33 and a low of $10.78.

What is the 52 week high and 52 week low for Keros Therapeutics Inc share?

Keros Therapeutics Inc share touched a 52 week high of $22.55 on and a 52 week low of $10.42 on . Keros Therapeutics Inc stock price today i.e. is closed at $11.13,which is 50.64% down from its 52 week high and 6.87% up from its 52 week low.

What is Keros Therapeutics Inc's market capitalisation today?

Keros Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Keros Therapeutics Inc Stock (KROS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Keros Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Keros Therapeutics Inc Shares that will get you 0.1348 shares as per Keros Therapeutics Inc share price of $11.13 per share as on April 14, 2026 at 1:29 am IST.

What is the minimum amount required to buy Keros Therapeutics Inc Stock (KROS) from India?

Indian investors can start investing in Keros Therapeutics Inc (KROS) shares with as little as ₹93.337 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹933.37 in Keros Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Keros Therapeutics Inc share’s latest price of $11.13 as on April 14, 2026 at 1:29 am IST, you will get 0.8985 shares of Keros Therapeutics Inc. Learn more about fractional shares .